Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection.
Highly pathogenic avian influenza (HPAI) viruses of the H5N1 subtype often cause severe pneumonia and multiple organ failure in humans, with reported case fatality rates of more than 60%. To develop a clinical antibody therapy, we generated a human-mouse chimeric monoclonal antibody (MAb) ch61 that...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/85e68b6456eb4b0ebb63a532351603e3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:85e68b6456eb4b0ebb63a532351603e3 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:85e68b6456eb4b0ebb63a532351603e32021-11-11T06:06:11ZProtective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection.1553-73661553-737410.1371/journal.ppat.1004192https://doaj.org/article/85e68b6456eb4b0ebb63a532351603e32014-06-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24945244/pdf/?tool=EBIhttps://doaj.org/toc/1553-7366https://doaj.org/toc/1553-7374Highly pathogenic avian influenza (HPAI) viruses of the H5N1 subtype often cause severe pneumonia and multiple organ failure in humans, with reported case fatality rates of more than 60%. To develop a clinical antibody therapy, we generated a human-mouse chimeric monoclonal antibody (MAb) ch61 that showed strong neutralizing activity against H5N1 HPAI viruses isolated from humans and evaluated its protective potential in mouse and nonhuman primate models of H5N1 HPAI virus infections. Passive immunization with MAb ch61 one day before or after challenge with a lethal dose of the virus completely protected mice, and partial protection was achieved when mice were treated 3 days after the challenge. In a cynomolgus macaque model, reduced viral loads and partial protection against lethal infection were observed in macaques treated with MAb ch61 intravenously one and three days after challenge. Protective effects were also noted in macaques under immunosuppression. Though mutant viruses escaping from neutralization by MAb ch61 were recovered from macaques treated with this MAb alone, combined treatment with MAb ch61 and peramivir reduced the emergence of escape mutants. Our results indicate that antibody therapy might be beneficial in reducing viral loads and delaying disease progression during H5N1 HPAI virus infection in clinical cases and combined treatment with other antiviral compounds should improve the protective effects of antibody therapy against H5N1 HPAI virus infection.Yasushi ItohReiko YoshidaShintaro ShichinoheMegumi HiguchiHirohito IshigakiMisako NakayamaVan Loi PhamHideaki IshidaMitsutaka KitanoMasahiko ArikataNaoko KitagawaYachiyo MitsuishiKazumasa OgasawaraHideaki TsuchiyaTakahiro HionoMasatoshi OkamatsuYoshihiro SakodaHiroshi KidaMutsumi ItoLe Quynh MaiYoshihiro KawaokaHiroko MiyamotoMari IshijimaManabu IgarashiYasuhiko SuzukiAyato TakadaPublic Library of Science (PLoS)articleImmunologic diseases. AllergyRC581-607Biology (General)QH301-705.5ENPLoS Pathogens, Vol 10, Iss 6, p e1004192 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5 |
| spellingShingle |
Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5 Yasushi Itoh Reiko Yoshida Shintaro Shichinohe Megumi Higuchi Hirohito Ishigaki Misako Nakayama Van Loi Pham Hideaki Ishida Mitsutaka Kitano Masahiko Arikata Naoko Kitagawa Yachiyo Mitsuishi Kazumasa Ogasawara Hideaki Tsuchiya Takahiro Hiono Masatoshi Okamatsu Yoshihiro Sakoda Hiroshi Kida Mutsumi Ito Le Quynh Mai Yoshihiro Kawaoka Hiroko Miyamoto Mari Ishijima Manabu Igarashi Yasuhiko Suzuki Ayato Takada Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection. |
| description |
Highly pathogenic avian influenza (HPAI) viruses of the H5N1 subtype often cause severe pneumonia and multiple organ failure in humans, with reported case fatality rates of more than 60%. To develop a clinical antibody therapy, we generated a human-mouse chimeric monoclonal antibody (MAb) ch61 that showed strong neutralizing activity against H5N1 HPAI viruses isolated from humans and evaluated its protective potential in mouse and nonhuman primate models of H5N1 HPAI virus infections. Passive immunization with MAb ch61 one day before or after challenge with a lethal dose of the virus completely protected mice, and partial protection was achieved when mice were treated 3 days after the challenge. In a cynomolgus macaque model, reduced viral loads and partial protection against lethal infection were observed in macaques treated with MAb ch61 intravenously one and three days after challenge. Protective effects were also noted in macaques under immunosuppression. Though mutant viruses escaping from neutralization by MAb ch61 were recovered from macaques treated with this MAb alone, combined treatment with MAb ch61 and peramivir reduced the emergence of escape mutants. Our results indicate that antibody therapy might be beneficial in reducing viral loads and delaying disease progression during H5N1 HPAI virus infection in clinical cases and combined treatment with other antiviral compounds should improve the protective effects of antibody therapy against H5N1 HPAI virus infection. |
| format |
article |
| author |
Yasushi Itoh Reiko Yoshida Shintaro Shichinohe Megumi Higuchi Hirohito Ishigaki Misako Nakayama Van Loi Pham Hideaki Ishida Mitsutaka Kitano Masahiko Arikata Naoko Kitagawa Yachiyo Mitsuishi Kazumasa Ogasawara Hideaki Tsuchiya Takahiro Hiono Masatoshi Okamatsu Yoshihiro Sakoda Hiroshi Kida Mutsumi Ito Le Quynh Mai Yoshihiro Kawaoka Hiroko Miyamoto Mari Ishijima Manabu Igarashi Yasuhiko Suzuki Ayato Takada |
| author_facet |
Yasushi Itoh Reiko Yoshida Shintaro Shichinohe Megumi Higuchi Hirohito Ishigaki Misako Nakayama Van Loi Pham Hideaki Ishida Mitsutaka Kitano Masahiko Arikata Naoko Kitagawa Yachiyo Mitsuishi Kazumasa Ogasawara Hideaki Tsuchiya Takahiro Hiono Masatoshi Okamatsu Yoshihiro Sakoda Hiroshi Kida Mutsumi Ito Le Quynh Mai Yoshihiro Kawaoka Hiroko Miyamoto Mari Ishijima Manabu Igarashi Yasuhiko Suzuki Ayato Takada |
| author_sort |
Yasushi Itoh |
| title |
Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection. |
| title_short |
Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection. |
| title_full |
Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection. |
| title_fullStr |
Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection. |
| title_full_unstemmed |
Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection. |
| title_sort |
protective efficacy of passive immunization with monoclonal antibodies in animal models of h5n1 highly pathogenic avian influenza virus infection. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2014 |
| url |
https://doaj.org/article/85e68b6456eb4b0ebb63a532351603e3 |
| work_keys_str_mv |
AT yasushiitoh protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT reikoyoshida protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT shintaroshichinohe protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT megumihiguchi protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT hirohitoishigaki protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT misakonakayama protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT vanloipham protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT hideakiishida protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT mitsutakakitano protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT masahikoarikata protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT naokokitagawa protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT yachiyomitsuishi protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT kazumasaogasawara protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT hideakitsuchiya protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT takahirohiono protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT masatoshiokamatsu protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT yoshihirosakoda protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT hiroshikida protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT mutsumiito protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT lequynhmai protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT yoshihirokawaoka protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT hirokomiyamoto protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT mariishijima protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT manabuigarashi protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT yasuhikosuzuki protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection AT ayatotakada protectiveefficacyofpassiveimmunizationwithmonoclonalantibodiesinanimalmodelsofh5n1highlypathogenicavianinfluenzavirusinfection |
| _version_ |
1718439510721691648 |